Rezvoglar KwikPen (Subcutaneous)

Generic name:insulin glargine-aglr, recombinant (subcutaneous route) [ IN-su-lin-GLAR-jeen, ree-KOM-bi-nant-- aglr ]
Drug class:Insulin

Medically reviewed by Drugs.com. Last updated on May 2, 2022.

Commonly used brand name(s)

In the U.S.

• Rezvoglar KwikPen

In Canada

• Lantus

Pharmacologic Class: Insulin Glargine, Recombinant

Uses for Rezvoglar KwikPen

Insulin glargine-aglr injection is a long-acting type of insulin that works slowly, over about 24 hours. Insulin is one of many hormones that help the body turn the food we eat into energy. This is done by using the glucose (sugar) in the blood as quick energy. Also, insulin helps us store energy that we can use later. When you have diabetes mellitus, your body cannot make enough insulin or does not use insulin properly. This causes you to have too much sugar in your blood. Like other types of insulin, insulin glargine-aglr is used to keep your blood sugar level close to normal. You may have to use insulin glargine-aglr in combination with another type of insulin or with a type of oral diabetes medicine to keep your blood sugar under control.

This medicine is available only with your doctor's prescription.

Before using Rezvoglar KwikPen

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of Rezvoglar™ to treat type 1 diabetes in children 6 years of age and older. However, safety and efficacy of Rezvoglar™ have not been established in children younger than 6 years of age with type 1 diabetes and in children with type 2 diabetes.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of Rezvoglar™ in the elderly. However, elderly patients are more likely to have unwanted effects (eg, heart problems, low blood sugar), which may require caution in patients receiving this medicine.

Breastfeeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional ...